

Gilbert R Thompson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7192338/publications.pdf>

Version: 2024-02-01

41
papers

2,003
citations

361413

20
h-index

276875

41
g-index

43
all docs

43
docs citations

43
times ranked

1420
citing authors

#	ARTICLE	IF	CITATIONS
1	Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 1990, 322, 1494-1499.	27.0	582
2	LDL apheresis. <i>Atherosclerosis</i> , 2003, 167, 1-13.	0.8	173
3	History and Development of Plant Sterol and Stanol Esters for Cholesterol-Lowering Purposes. <i>American Journal of Cardiology</i> , 2005, 96, 3-9.	1.6	122
4	Efficacy criteria and cholesterol targets for LDL apheresis. <i>Atherosclerosis</i> , 2010, 208, 317-321.	0.8	115
5	Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. <i>Current Opinion in Lipidology</i> , 2010, 21, 492-498.	2.7	95
6	Current management of severe homozygous hypercholesterolaemias. <i>Current Opinion in Lipidology</i> , 2004, 15, 413-422.	2.7	88
7	Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. <i>European Heart Journal</i> , 2018, 39, 1162-1168.	2.2	81
8	HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. <i>Atherosclerosis</i> , 2016, 255, 128-139.	0.8	76
9	Comparison of Efficacy of Plant Stanol Ester and Sterol Ester: Short-Term and Longer-Term Studies. <i>American Journal of Cardiology</i> , 2005, 96, 29-36.	1.6	67
10	Current Role of Lipoprotein Apheresis. <i>Current Atherosclerosis Reports</i> , 2019, 21, 26.	4.8	63
11	Determinants of Variable Response to Statin Treatment in Patients With Refractory Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 832-837.	2.4	58
12	The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. <i>Atherosclerosis Supplements</i> , 2013, 14, 67-70.	1.2	56
13	Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances. <i>Current Atherosclerosis Reports</i> , 2015, 17, 465.	4.8	53
14	The extracranial carotid artery in familial hypercholesterolaemia: relationship of intimal-medial thickness and plaque morphology with plasma lipids and coronary heart disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1996, 3, 61-67.	1.5	46
15	Lipoprotein apheresis. <i>Current Opinion in Lipidology</i> , 2010, 21, 487-491.	2.7	44
16	Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes. <i>Atherosclerosis</i> , 2015, 243, 328-333.	0.8	37
17	Additive Effects of Plant Sterol and Stanol Esters to Statin Therapy. <i>American Journal of Cardiology</i> , 2005, 96, 37-39.	1.6	27
18	Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989â€“2017. <i>Atherosclerosis</i> , 2019, 290, 44-51.	0.8	25

#	ARTICLE	IF	CITATIONS
19	Novel lipid-regulating drugs. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2619-2628.	4.1	24
20	Management of dyslipidaemia. <i>Heart</i> , 2004, 90, 949-955.	2.9	24
21	Managing homozygous familial hypercholesterolaemia from cradle to grave. <i>Atherosclerosis Supplements</i> , 2015, 18, 16-20.	1.2	18
22	The scientific basis and future of lipoprotein apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 32-36.	0.9	16
23	Plasma Lipid and Lipoprotein Abnormalities in Patients with Malabsorption. <i>Clinical Science and Molecular Medicine</i> , 1973, 45, 583-592.	0.8	14
24	Lipoprotein(a): the underestimated cardiovascular risk factor. <i>Heart</i> , 2014, 100, 534-535.	2.9	14
25	Normal and Pathological Lipoprotein Metabolism. <i>Drugs</i> , 1988, 36, 51-54.	10.9	10
26	The Role of Low Density Lipoprotein Apheresis in the Treatment of Familial Hypercholesterolemia. <i>Therapeutic Apheresis and Dialysis</i> , 1997, 1, 13-16.	0.6	9
27	The Effect of Cholesterol Reduction with Fluvastatin on Aortic Compliance, Coronary Calcification and Carotid Intimal-Medial Thickness: A Pilot Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1998, 5, 1-10.	2.8	9
28	Screening relatives of patients with premature coronary heart disease. <i>British Heart Journal</i> , 2002, 87, 390-394.	2.1	8
29	Lipoprotein apheresis for the treatment of familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2013, 8, 573-586.	0.4	6
30	Atherosclerosis in cholesterol-fed rabbits and in homozygous and heterozygous LDL receptor-deficient humans. <i>Atherosclerosis</i> , 2018, 276, 148-154.	0.8	6
31	PCSK9 Inhibitors for Homozygous Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020, 76, 143-145.	2.8	6
32	Antherosclerosis and hyperlipidaemia: Genetic polymorphism and plasma lipoproteins. <i>Nature</i> , 1983, 301, 658-658.	27.8	5
33	Goals of statin therapy: Three viewpoints. <i>Current Atherosclerosis Reports</i> , 2002, 4, 26-33.	4.8	5
34	FH through the retrospectoscope. <i>Journal of Lipid Research</i> , 2021, 62, 100036.	4.2	5
35	New prospects for lipid-lowering drugs. <i>Expert Opinion on Investigational Drugs</i> , 1998, 7, 715-727.	4.1	4
36	Limitations of cholesterol lowering with PCSK9 inhibitors. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 241-243.	11.4	4

#	ARTICLE	IF	CITATIONS
37	Use of apheresis in the age of new therapies for familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2021, 32, 363-369.	2.7	4
38	Treatment of hyperlipidaemia. <i>Clinical Endocrinology</i> , 1993, 38, 337-342.	2.4	1
39	The Lipid Hypothesis. <i>Acta Medica Scandinavica</i> , 1980, 208, 341-342.	0.0	1
40	Clinical pharmacology: New hopes for the treatment of coronary heart disease. <i>Nature</i> , 1986, 324, 412-412.	27.8	0
41	Obituary of Dr N.B. Myant. <i>Atherosclerosis</i> , 2015, 240, 437-438.	0.8	0